311 related articles for article (PubMed ID: 37319357)
1. The Dichotomy of Interleukin-9 Function in the Tumor Microenvironment.
Cannon A; Pajulas A; Kaplan MH; Zhang J
J Interferon Cytokine Res; 2023 Jun; 43(6):229-245. PubMed ID: 37319357
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
[No Abstract] [Full Text] [Related]
3. Unveiling the multifaceted antitumor effects of interleukin 33.
Arrizabalaga L; Risson A; Ezcurra-Hualde M; Aranda F; Berraondo P
Front Immunol; 2024; 15():1425282. PubMed ID: 38881897
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-1 receptor accessory protein (IL-1RAP): A magic bullet candidate for immunotherapy of human malignancies.
Zarezadeh Mehrabadi A; Shahba F; Khorramdelazad H; Aghamohammadi N; Karimi M; Bagherzadeh K; Khoshmirsafa M; Massoumi R; Falak R
Crit Rev Oncol Hematol; 2024 Jan; 193():104200. PubMed ID: 37981104
[TBL] [Abstract][Full Text] [Related]
5. Targeting the IL-9 pathway in cancer immunotherapy.
Zheng N; Lu Y
Hum Vaccin Immunother; 2020 Oct; 16(10):2333-2340. PubMed ID: 32040369
[TBL] [Abstract][Full Text] [Related]
6. IL-33/ST2 as a potential target for tumor immunotherapy.
Jiang W; Lian J; Yue Y; Zhang Y
Eur J Immunol; 2021 Aug; 51(8):1943-1955. PubMed ID: 34131922
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-33, a Potential Cytokine Expressed in Tumor Microenvironment Involves in Antitumor Immunotherapy Through Facilitates CD8
Li X; Lv Q; Feng Y; Gu Y; Xia R; Ma J; He H; Zhu Y
J Interferon Cytokine Res; 2018 Nov; 38(11):491-499. PubMed ID: 30452317
[TBL] [Abstract][Full Text] [Related]
8. The Pro-tumorigenic IL-33 Involved in Antitumor Immunity: A Yin and Yang Cytokine.
Fournié JJ; Poupot M
Front Immunol; 2018; 9():2506. PubMed ID: 30416507
[TBL] [Abstract][Full Text] [Related]
9. Tumor cell-derived LC3B
Chen YQ; Man ZS; Zheng L; Zhang Y; Zhao CW; Ma YT; Zhou J; Wang P; Yu Y; Gu F; Niu GP
Clin Immunol; 2024 Apr; 261():109925. PubMed ID: 38310993
[TBL] [Abstract][Full Text] [Related]
10. Vector Aided Microenvironment programming (VAMP): reprogramming the TME with MVA virus expressing IL-12 for effective antitumor activity.
Seclì L; Infante L; Nocchi L; De Lucia M; Cotugno G; Leoni G; Micarelli E; Garzia I; Avalle L; Sdruscia G; Troise F; Allocca S; Romano G; Scarselli E; D'Alise AM
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37117006
[TBL] [Abstract][Full Text] [Related]
11. Interleukin (IL)-7 Signaling in the Tumor Microenvironment.
Bednarz-Misa I; Bromke MA; Krzystek-Korpacka M
Adv Exp Med Biol; 2021; 1290():9-49. PubMed ID: 33559853
[TBL] [Abstract][Full Text] [Related]
12. Viral Vectors Expressing Interleukin 2 for Cancer Immunotherapy.
Wang H; Borlongan M; Hemminki A; Basnet S; Sah N; Kaufman HL; Rabkin SD; Saha D
Hum Gene Ther; 2023 Sep; 34(17-18):878-895. PubMed ID: 37578106
[TBL] [Abstract][Full Text] [Related]
13. Dynamic changes of soluble HLA-G and cytokine plasma levels in cervical cancer patients: potential role in cancer progression and immunotherapy.
Xu HH; Xie YY; Jun-Gan ; Yang Z; Han QY
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4195-4204. PubMed ID: 36053326
[TBL] [Abstract][Full Text] [Related]
14. Recombinant virus-like particles presenting IL-33 successfully modify the tumor microenvironment and facilitate antitumor immunity in a model of breast cancer.
Feng X; Liu H; Chu X; Sun P; Huang W; Liu C; Yang X; Sun W; Bai H; Ma Y
Acta Biomater; 2019 Dec; 100():316-325. PubMed ID: 31542504
[TBL] [Abstract][Full Text] [Related]
15. Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type.
Fabre J; Giustiniani J; Garbar C; Antonicelli F; Merrouche Y; Bensussan A; Bagot M; Al-Dacak R
Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27589729
[TBL] [Abstract][Full Text] [Related]
16. [Interleukin-33: Friend or Enemy in the Fight against Tumors?].
Gorbacheva AM; Mitkin NA
Mol Biol (Mosk); 2019; 53(5):774-789. PubMed ID: 31661477
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of cancer by IL-12-based cytokine combinations.
Weiss JM; Subleski JJ; Wigginton JM; Wiltrout RH
Expert Opin Biol Ther; 2007 Nov; 7(11):1705-21. PubMed ID: 17961093
[TBL] [Abstract][Full Text] [Related]
18. New perspectives in cancer immunotherapy: targeting IL-6 cytokine family.
Soler MF; Abaurrea A; Azcoaga P; Araujo AM; Caffarel MM
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37945321
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of MC38 colon cancer growth by multicomponent chemoimmunotherapy with anti-IL-10R antibodies, HES-MTX nanoconjugate, depends on application of IL-12, IL-15 or IL-18 secreting dendritic cell vaccines.
Węgierek-Ciura K; Mierzejewska J; Szczygieł A; Rossowska J; Wróblewska A; Świtalska M; Goszczyński TM; Szermer-Olearnik B; Pajtasz-Piasecka E
Front Immunol; 2023; 14():1212606. PubMed ID: 37545526
[TBL] [Abstract][Full Text] [Related]
20. Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses.
Brempelis KJ; Cowan CM; Kreuser SA; Labadie KP; Prieskorn BM; Lieberman NAP; Ene CI; Moyes KW; Chinn H; DeGolier KR; Matsumoto LR; Daniel SK; Yokoyama JK; Davis AD; Hoglund VJ; Smythe KS; Balcaitis SD; Jensen MC; Ellenbogen RG; Campbell JS; Pierce RH; Holland EC; Pillarisetty VG; Crane CA
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33115946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
